The latest biotech news

neurological disorders memory blocking uk

News and Trends 7 Nov 2017

British Researchers Find Thought Police to Treat Neurological Disorders

Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […]

November 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Nov 2017

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […]

November 6, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Nov 2017

German Biotech Teams Up with BioNTech to Boost Antibody Development

MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […]

November 6, 2017 - 1 minutemin - By Alex Dale

advicenne distal renal tubular acidosis rare disease

News and Trends 6 Nov 2017

Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech

Update (6/11/2017): ADV7103 has maintained its efficacy in a 6-month extension of the Phase III study. In 79% of the patients, the blood bicarbonate levels were kept within the normal range after 6 months of treatment, further supporting its push to become the first treatment for the disease on the market. Originally published 11/9/2017 Advicenne has […]

November 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Nov 2017

Get your Company Ready for the EU’s New Data Protection Law

With the beginning of summer next year, not only temperatures will rise, but possibly also temperaments, as the European Union’s new data protection law takes effect. The highly tightened measures to protect personal data will mean that companies worldwide have a lot of adjusting to do. Like most new regulations, the General Data Protection Regulation […]

November 6, 2017 - 9 minutesmins - By External Contributor

News and Trends 6 Nov 2017

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

NousCom is developing semi-personalized medicine that convinced investors like Abingworth to go in big for its off-the-shelf neoantigen vaccines. Based in Basel and run by a team of serial entrepreneurs with over 15 years of experience, NousCom is finding the middle ground between broadly applicable treatments and personalized medicine. “We are the only company working […]

November 6, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 4 Nov 2017

Bioart from the Ocean Depths: Underwater Sounds

What can art tell us about the mysteries of underwater life? Robertina Šebjanič explores the fascinating world of jellyfish, shrimps, fish and sea urchins. Robertina Šebjanič is an artist and researcher fascinated by underwater life. Her work explores the relationship between humans and animals, often through an unusual medium: sound. Šebjanič collaborates with other artists, […]

November 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its gene therapy for hemophilia B will enter Phase III trials. Originally published on 24/10/2017 UniQure launched a public offering, perfectly timed with a rise in […]

November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

British Researchers Find Thought Police to Treat Neurological Disorders

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

German Biotech Teams Up with BioNTech to Boost Antibody Development

Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech

Get your Company Ready for the EU’s New Data Protection Law

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

Bioart from the Ocean Depths: Underwater Sounds

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!